Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
According to a recent study conducted by scientists at Emory University in Atlanta, the administration of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive type of skin cancer, expedited their metastatic bone growth.
A minimally invasive technique was created and improved by scientists at Terasaki Institute for Biomedical Innovation (TIBI) to develop immunotherapeutic cancer treatments.
A discovery regarding how a particular protein is triggered in tumor cells, conducted by researchers at the University of California, Irvine, may lead to more effective therapies for some of the deadliest types of cancer.
Cancer cells can have thousands of mutations in their DNA. However, only a handful of those actually drive the progression of cancer; the rest are just along for the ride.
The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.
In cancer management, biomarkers are commonly used to guide treatment decisions and evaluate patient outcomes.
Researchers at Emory University have uncovered a mechanism for skin cell death that might lead to novel therapies for “flesh-eating” infections, alopecia, hives, and possibly even melanoma, the deadliest type of skin cancer.
Many cancer patients have benefited from the development of anti-cancer immunotherapy drugs known as immune checkpoint inhibitors, but patients with mucosal melanomas—melanomas that occur in the mucous membranes of the head, neck, eyes, respiratory system, and genitourinary region rather than on the skin—are highly resistive to immune checkpoint inhibitors for reasons researchers do not fully understand.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
Melanoma is a somewhat unusual cancer-;one that blooms before our very eyes, often on sun-exposed skin, and can quickly become deadly as it turns our own skin against us and spreads to other organs.
Natural killer (NK) cells, which are part of the body’s innate, or first-line, immune response, interact with tumor cells, viral infections, and solid organ transplants, according to a new study.
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
Cutaneous T-cell lymphoma (CTCL) is an incurable, rare cancer of skin-homing T cells that is highly disfiguring and lethal at advanced stages.
Melanoma patients receiving therapy that helps their immune system kill cancer cells respond to treatment differently depending on the types of microbes in their gut, and new research suggests the microorganisms hindering therapy have more influence than the beneficial ones.
The Translational Genomics Research Institute, an affiliate of City of Hope, is partnering with a Silicon Valley firm to become one of the first research institutes in the world to employ a new Artificial Intelligence-powered imaging and sorting technology to classify and isolate individual diseased cells.
It is estimated that about a quarter of cancer patients are at risk of brain metastases, a rate that is increasing especially among those who suffer relapses after having undergone different cancer treatments.
Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease
Researchers have created a new technology that allows them to use immune cells from tumors to combat cancer more quickly and efficiently.
A study published today in Cell Reports reveals important insights into the molecular mechanisms that underpin the body's natural defenses against the development of skin cancer.
An olfactory receptor gene that aids in the sense of smell may also play a role in the metastasis of breast cancer to the brain, bones and lung, researchers from Massachusetts General Hospital have found.